rethinkPeptides Search
Menu
Study breakdown

Vasoactive Intestinal Peptide May Drive Myopia Through Eye Growth Signaling

evidence
The takeaway

VIP plays a significant role in myopia pathogenesis through regulation of ocular growth signaling, offering potential as both a biomarker and therapeutic target for myopia control.

Eye growth peptide

VIP regulates signaling pathways controlling eye elongation — the fundamental process underlying myopia development

What the researchers found

VIP is involved in myopia pathogenesis through ocular growth signaling pathways, with potential as a biomarker and therapeutic target for myopia control.

Why it matters

Myopia is becoming epidemic and can lead to blindness. Understanding VIP's role could lead to peptide-based treatments that slow myopic progression.

How the study worked

Review of molecular mechanisms, expression studies, and experimental evidence linking VIP to myopia/ocular growth regulation.

What this study cannot tell us

Mostly preclinical and molecular evidence. Human clinical validation of VIP as myopia biomarker needed. Therapeutic targeting not yet tested.

How to read the evidence

Review of molecular and preclinical evidence. Emerging field with strong mechanistic rationale.

When this study was published

Published in 2025.

The bigger picture

Identifying neuropeptides involved in eye growth opens entirely new therapeutic approaches for myopia beyond current optical interventions (glasses, contacts).

Questions still open

  • Could VIP-targeting eye drops slow myopia progression?
  • Is VIP measurable in tears as a non-invasive myopia biomarker?
  • How does VIP interact with other myopia-related signaling (dopamine, retinoic acid)?

Common questions

What causes myopia?
Myopia occurs when the eye grows too long. VIP (vasoactive intestinal peptide) appears to regulate the signaling pathways that control this growth, suggesting it plays a key role in who develops nearsightedness.
Could this lead to new myopia treatments?
Potentially. If VIP signaling drives eye growth, drugs that modify VIP activity in the eye could slow myopia progression — a major unmet need as myopia rates skyrocket globally.

Read the original research

Myopia pathogenesis and vasoactive intestinal peptide: Molecular mechanisms, experimental models, and clinical implications.

Experimental eye research, 263, 110810

Citation

Grubsic, Camila; Céspedes, Ricardo; Tapia, Felipe; Schmachtenberg, Oliver. (2026). Myopia pathogenesis and vasoactive intestinal peptide: Molecular mechanisms, experimental models, and clinical implications.. Experimental eye research, 263, 110810. https://doi.org/10.1016/j.exer.2025.110810